

## Security Health Plan releases new updates to prior authorizations and post service claim edits

Security Health Plan requires prior authorization (PA) and post service claim edits (PSCE) on medications in order to ensure coverage and payment for those services.

A number of requirements have been added for 2023 as we work to make sure all care, services and treatments are medically necessary.

Magellan will implement additional PA's & PSCE's April 1, 2023, which include:

Specialty Drugs in the office based and outpatient settings

- Hemgenix<sup>®</sup> (etranacogene dezaparvovec-drlb)
- Tzield<sup>®</sup> (teplizumab-mzwv)
- Elahere<sup>®</sup> (mirvetuximab soravtansine)
- Imjudo<sup>®</sup> (tremelimumab-actl)
- Tecayli<sup>®</sup> (teclistamab-cqyv)
- Pedmark<sup>®</sup> (sodium thiosulfate)
- Vegzelma<sup>®</sup> (bevacizumab-adcd)
- Rolvedon<sup>®</sup> (eflapegrastim-xnst)
- Adstiladrin<sup>®</sup> (nadofaragene firadenovec-vncg)  
(bendamustine hydrochloride injection)
- Vivimusta<sup>®</sup> injection)
- Skysona<sup>®</sup> (elivaldogene autotemcel)
- Lunsumio<sup>®</sup> (mosunetuzumab-axgb)
- lanreotide

Magellan will implement additional PSCE's April 1, 2023, which include:

- Tyvaso<sup>®</sup> (treprostinil)

To view the complete list of medications that will require a prior authorization and/or post service claim edit, visit <https://www.securityhealth.org/providers/medical-pharmacy>.

You can also reach out to the Security Health Plan Provider Relations Department at 1-800-548-1224.